MX2017011951A - Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso. - Google Patents
Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso.Info
- Publication number
- MX2017011951A MX2017011951A MX2017011951A MX2017011951A MX2017011951A MX 2017011951 A MX2017011951 A MX 2017011951A MX 2017011951 A MX2017011951 A MX 2017011951A MX 2017011951 A MX2017011951 A MX 2017011951A MX 2017011951 A MX2017011951 A MX 2017011951A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- novel
- methods
- pharmaceutical compositions
- substituted derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Se proporciona un compuesto de la Fórmula I: o enantiómeros, sales o solvatos farmacéuticamente aceptables del mismo. La invención también se relaciona al uso de los compuestos de la Fórmula I como inhibidores de TDO2. La invención también se relaciona con eld uso de los compuestos de la Fórmula I para el tratamiento y/o prevención del cáncer, trastornos neurodegenerativos tal como enfermedad de Parkinson, enfermedad de Alzheimer y enfermedad de Huntington, infecciones virales crónicas tales como VCH y VIH, depresión, y obesidad. La invención también se relaciona con un proceso para fabricar compuestos de la Fórmula I.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2015/051957 WO2015140717A1 (en) | 2014-03-18 | 2015-03-17 | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
US201562203032P | 2015-08-10 | 2015-08-10 | |
PCT/IB2016/051509 WO2016147144A1 (en) | 2015-03-17 | 2016-03-17 | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017011951A true MX2017011951A (es) | 2018-06-15 |
Family
ID=56919874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017011951A MX2017011951A (es) | 2015-03-17 | 2016-03-17 | Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso. |
Country Status (14)
Country | Link |
---|---|
US (1) | US9873690B2 (es) |
EP (1) | EP3271354A1 (es) |
JP (1) | JP6775516B2 (es) |
KR (1) | KR102013512B1 (es) |
CN (1) | CN107635990A (es) |
AU (1) | AU2016231832B2 (es) |
BR (1) | BR112017019699A2 (es) |
CA (1) | CA2979616C (es) |
HK (1) | HK1243999A1 (es) |
IL (1) | IL254124A0 (es) |
MX (1) | MX2017011951A (es) |
RU (1) | RU2672252C1 (es) |
SG (1) | SG11201706992TA (es) |
WO (1) | WO2016147144A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160336813A1 (en) | 2015-05-15 | 2016-11-17 | NeuSpera Medical Inc. | Midfield coupler |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
WO2018115984A1 (en) | 2016-12-19 | 2018-06-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
MX2019012038A (es) | 2017-05-30 | 2019-11-18 | Bristol Myers Squibb Co | Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico. |
JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | Dll3結合タンパク質および使用方法 |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
CN111166735B (zh) * | 2020-01-15 | 2023-08-18 | 延边大学 | 邻苯二甲酸-双-(2-乙基庚基)酯在抑制脂肪蓄积中的应用 |
CN111499592B (zh) * | 2020-03-14 | 2023-06-23 | 江苏省农用激素工程技术研究中心有限公司 | 5-氨甲基糖精的合成方法 |
IL297743B1 (en) | 2020-04-30 | 2024-02-01 | Medshine Discovery Inc | Compounds containing benzosulatum |
JP2023532768A (ja) | 2020-07-07 | 2023-07-31 | バイオエヌテック エスエー | Hpv陽性癌の治療用rna |
CN111777557B (zh) * | 2020-07-28 | 2022-11-22 | 中国科学院上海有机化学研究所 | 以芳香联苯烯为骨架的新型抗肿瘤先导化合物及其应用 |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE509731C2 (sv) | 1996-05-14 | 1999-03-01 | Labwell Ab | Metod för palladium-katalyserade organiska reaktioner innefattande ett uppvärmningssteg utfört med mikrovågsenergi |
JP2000095759A (ja) | 1998-07-21 | 2000-04-04 | Takeda Chem Ind Ltd | 三環性化合物、その製造法および剤 |
US6265403B1 (en) | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
MXPA04002070A (es) | 2001-09-19 | 2004-06-07 | Pharmacia Corp | Compuestos de indazol sustituidos para el tratamiento de la inflamacion. |
AU2003214414B2 (en) | 2002-03-28 | 2008-10-09 | Eisai R & D Management Co., Ltd. | Azaindoles as inhibitors of c-Jun N-terminal kinases |
TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
FR2845996A1 (fr) | 2002-10-16 | 2004-04-23 | Servier Lab | Nouveaux derives de[3,4-a:3,4-c]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP2006521377A (ja) * | 2003-03-27 | 2006-09-21 | ランケナー インスティテュート フォー メディカル リサーチ | 新型ido阻害剤とその使用方法 |
CN1794986B (zh) | 2003-03-27 | 2012-09-05 | 兰肯瑙医学研究所 | 治疗癌症的新药物 |
FR2862647B1 (fr) | 2003-11-25 | 2008-07-04 | Aventis Pharma Sa | Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant |
GB0328909D0 (en) | 2003-12-12 | 2004-01-14 | Syngenta Participations Ag | Chemical compounds |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
CN101087784A (zh) * | 2004-09-21 | 2007-12-12 | 阿特西斯公司 | 显示crth2受体拮抗性的吲哚乙酸及其应用 |
RU2547148C2 (ru) | 2005-02-09 | 2015-04-10 | Аркьюл, Инк. | Композиции и способы лечения рака |
WO2007039580A1 (en) | 2005-10-05 | 2007-04-12 | Nycomed Gmbh | Imidazolyl-substituted benzophenone compounds |
WO2007045622A1 (en) | 2005-10-18 | 2007-04-26 | Nycomed Gmbh | Oxazolo [4 , 5-b] pyridine compounds as nitric oxide synthase inhibitors |
EP1940787A4 (en) * | 2005-10-27 | 2009-07-01 | Lankenau Inst Medical Res | NOVEL IDO INHIBITORS AND METHODS OF USE |
MY146494A (en) | 2006-01-24 | 2012-08-15 | Lilly Co Eli | Indole sulfonamide modulators of progesterone receptors |
CA2644910C (en) | 2006-03-31 | 2014-01-28 | Abbott Laboratories | Indazole compounds |
KR20140019032A (ko) | 2006-04-05 | 2014-02-13 | 노파르티스 아게 | 암을 치료하기 위한 치료제의 조합물 |
GB0624308D0 (en) | 2006-12-05 | 2007-01-17 | Molmed Spa | Combination product |
RU2009125620A (ru) | 2006-12-07 | 2011-01-20 | Новартис АГ (CH) | Органические соединения |
MX2009008253A (es) | 2007-01-31 | 2009-10-12 | Vertex Pharma | Derivados de 2-aminopiridina utiles como inhibidores de cinasa. |
WO2008115804A1 (en) | 2007-03-16 | 2008-09-25 | Lankenau Institute For Medical Research | Novel ido inhibitors and methods of use thereof |
US20100317863A1 (en) | 2007-07-25 | 2010-12-16 | Boehringer Ingelheim International Gmbh | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof |
US7868001B2 (en) | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
WO2009073497A2 (en) | 2007-11-30 | 2009-06-11 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
CA2719457C (en) | 2008-03-24 | 2017-05-02 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
US20110159017A1 (en) | 2008-04-11 | 2011-06-30 | Ludwig Institute For Cancer Research Ltd. | Trytophan catabolism in cancer treatment and diagnosis |
CN104042611B (zh) * | 2008-07-08 | 2019-05-14 | 因塞特控股公司 | 作为吲哚胺2,3-双加氧酶的抑制剂的1,2,5-噁二唑 |
DE102008052943A1 (de) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
MX2011006171A (es) | 2008-12-19 | 2011-06-20 | Squibb Bristol Myers Co | Compuestos de carbazol carboxamida utiles como inhibidores de cinasa. |
EP2398810A1 (en) | 2009-02-17 | 2011-12-28 | Vertex Pharmaceuticals Incorporated | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase |
EP2451811A1 (en) | 2009-05-27 | 2012-05-16 | F. Hoffmann-La Roche AG | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
EP2480080A4 (en) | 2009-09-23 | 2014-01-08 | Medivation Technologies Inc | PYRIDO [3,4-B] INDOLES AND METHODS OF USE |
WO2011045224A1 (de) | 2009-10-12 | 2011-04-21 | Bayer Cropscience Ag | 1- (pyrid-3-yl) -pyrazole und 1- (pyrimid-5-yl) -pyrazole als schädlingsbekämpfungsmittel |
ES2749504T3 (es) | 2009-10-13 | 2020-03-20 | Ligand Pharm Inc | Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos |
JP6261340B2 (ja) | 2010-11-18 | 2018-01-17 | リガンド ファーマシューティカルズ インコーポレイテッド | 造血成長因子模倣体の使用 |
CA2830780A1 (en) | 2011-03-22 | 2012-09-27 | Amgen Inc. | Azole compounds as pim inhibitors |
BR112013029640A2 (pt) | 2011-05-23 | 2017-06-13 | Merck Patent Gmbh | derivados de piridina e pirazina |
WO2013025883A1 (en) | 2011-08-17 | 2013-02-21 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
US9126984B2 (en) | 2013-11-08 | 2015-09-08 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
US20160263087A1 (en) | 2013-11-08 | 2016-09-15 | Iteos Therapeutics | Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
WO2015121812A1 (en) | 2014-02-12 | 2015-08-20 | Iteos Therapeutics | Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use |
WO2015140717A1 (en) * | 2014-03-18 | 2015-09-24 | Iteos Therapeutics | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
US20150266857A1 (en) * | 2014-03-18 | 2015-09-24 | Iteos Therapeutics | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
TWI567059B (zh) | 2014-05-15 | 2017-01-21 | 埃帝歐斯醫療公司 | 吡咯啶-2,5-二酮衍生物、醫藥組合物及用做為ido1抑制劑之方法 |
CA2994917A1 (en) * | 2015-08-10 | 2017-02-16 | Pfizer Inc. | 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
-
2016
- 2016-03-17 RU RU2017130845A patent/RU2672252C1/ru not_active IP Right Cessation
- 2016-03-17 WO PCT/IB2016/051509 patent/WO2016147144A1/en active Application Filing
- 2016-03-17 SG SG11201706992TA patent/SG11201706992TA/en unknown
- 2016-03-17 US US15/072,534 patent/US9873690B2/en not_active Expired - Fee Related
- 2016-03-17 EP EP16711022.0A patent/EP3271354A1/en not_active Withdrawn
- 2016-03-17 AU AU2016231832A patent/AU2016231832B2/en not_active Ceased
- 2016-03-17 CN CN201680028408.7A patent/CN107635990A/zh active Pending
- 2016-03-17 BR BR112017019699-9A patent/BR112017019699A2/pt not_active Application Discontinuation
- 2016-03-17 CA CA2979616A patent/CA2979616C/en not_active Expired - Fee Related
- 2016-03-17 JP JP2017548261A patent/JP6775516B2/ja active Active
- 2016-03-17 MX MX2017011951A patent/MX2017011951A/es unknown
- 2016-03-17 KR KR1020177029203A patent/KR102013512B1/ko active IP Right Grant
-
2017
- 2017-08-23 IL IL254124A patent/IL254124A0/en unknown
-
2018
- 2018-03-12 HK HK18103418.8A patent/HK1243999A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2979616A1 (en) | 2016-09-22 |
SG11201706992TA (en) | 2017-09-28 |
BR112017019699A2 (pt) | 2018-09-04 |
WO2016147144A1 (en) | 2016-09-22 |
KR20170132204A (ko) | 2017-12-01 |
EP3271354A1 (en) | 2018-01-24 |
US9873690B2 (en) | 2018-01-23 |
CN107635990A (zh) | 2018-01-26 |
RU2672252C1 (ru) | 2018-11-13 |
KR102013512B1 (ko) | 2019-08-22 |
JP6775516B2 (ja) | 2020-10-28 |
JP2018511587A (ja) | 2018-04-26 |
IL254124A0 (en) | 2017-10-31 |
CA2979616C (en) | 2020-04-28 |
US20160272628A1 (en) | 2016-09-22 |
AU2016231832A1 (en) | 2017-09-14 |
AU2016231832B2 (en) | 2019-09-19 |
HK1243999A1 (zh) | 2018-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017011951A (es) | Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso. | |
MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
MX2022005160A (es) | Oxisteroles y metodos de uso de los mismos. | |
TN2016000501A1 (en) | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors. | |
PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
MX2023001876A (es) | Derivados de rapamicina. | |
MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
EP4316591A3 (en) | Oxysterols and methods of use thereof | |
PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
PH12020551014A1 (en) | Amino-fluoropiperidine derivatives as kinase inhibitor | |
WO2019132561A8 (ko) | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 | |
PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
MY194468A (en) | Oxy-fluoropiperidine derivatives as kinase inhhiitor | |
JOP20170169A1 (ar) | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو | |
PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
MX2018001925A (es) | Composiciones que comprenden compuestos triciclicos heterociclicos. | |
MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
WO2015198263A3 (en) | Novel betulinic proline substituted derivatives as hiv inhibitors | |
MX2018002177A (es) | Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo. | |
MX2018015990A (es) | Compuestos terapeuticos. | |
PH12017501134A1 (en) | Fumagillol derivatives | |
MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
NZ748746A (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
WO2018080215A8 (en) | 3-AMINO ALKYLATED INDOLE DERIVATIVE, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF |